Table 3.
Dose response (linear ERR/Gy estimates) for selected leukaemia endpoints in relation to dose range used for fitting.
| Dose range | ERR/Gy ( + 95% CI) | Cases/deaths | P value | ERR/Gy ( + 95% CI) | Cases/deaths | P value |
|---|---|---|---|---|---|---|
| Acute myeloid leukaemia +myelodysplastic syndrome | Acute myeloid leukaemia | |||||
| Unrestricted | 1.430 (0.586, 2.725) | 158 | <0.0001 | 1.475 (0.591, 2.847) | 140 | <0.0001 |
| ≤1 Gy | −0.015 (−0.677, 1.103) | 142 | 0.9748 | −0.033 (−0.706, 1.139) | 125 | 0.9436 |
| ≤500 mGy | −0.566 (−1.943, 2.295) | 128 | 0.6143 | −1.440 (−2.580, 0.794) | 113 | 0.1590 |
| ≤300 mGy | 5.049 (−0.887, 15.62) | 124 | 0.1134 | 2.125 (−2.582, 10.76) | 110 | 0.4591 |
| ≤200 mGy | 15.40 (4.949, 33.04) | 124 | 0.0005 | 10.43 (1.845, 25.13) | 110 | 0.0100 |
| ≤100 mGy | 20.91 (4.080, 49.21) | 111 | 0.0081 | 15.56 (0.921, 40.61) | 99 | 0.0333 |
| Chronic myeloid leukaemia | Acute lymphoblastic leukaemia | |||||
| Unrestricted | 1.769 (0.384, 4.504) | 61 | 0.0029 | 6.654 (2.792, 14.83) | 71 | <0.0001 |
| ≤1 Gy | 0.346 (−0.776, 2.889) | 56 | 0.6596 | 2.934 (0.209, 9.310) | 62 | 0.0270 |
| ≤500 mGy | 0.074 (−3.156, 5.149) | 51 | 0.9643 | 4.219 (−0.600, 16.52) | 55 | 0.1141 |
| ≤300 mGy | 0.945 (−2.864, 10.30) | 49 | 0.7368 | 11.70 (−1.385, 51.91) | 51 | 0.1075 |
| ≤200 mGy | −3.614 (−8.839a, 6.602) | 46 | 0.3666 | 22.99 (1.027, 89.71) | 50 | 0.0330 |
| ≤100 mGy | −6.422 (−17.98a, 13.57) | 43 | 0.3939 | 46.60 (3.526, >100) | 47 | 0.0227 |
aWald-based CI.